Document Detail


CRD-BP: a c-Myc mRNA stabilizing protein with an oncofetal pattern of expression.
MedLine Citation:
PMID:  12894594     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The Coding Region Determinant-Binding Protein (CRD-BP) is an RRM and KH-domain-containing protein that recognizes specifically at least three RNAs. It binds to one of the two c-myc mRNA instability elements, to the 5'Un Translated Region (UTR) of the leader 3 IGF-II mRNA and to the oncofetal H19 RNA. CRD-BP has been assigned a role in stabilizing c-myc mRNA by preventing its endonucleolytic cleavage and in repressing the translation of the leader 3 IGF-II mRNA, the major embryonic species of this message. CRD-BP is normally expressed only in fetal tissues. However, its expression is detected in primary tumors and transformed cell lines of different origins. The vast majority of colon (80%) and breast (60%) tumors and sarcomas (73%) express CRD-BP whereas in other tumor types, for example prostate carcinomas, its expression is rare. CRD-BP expression has also been detected in benign tumors such as breast fibroadenomas, meningiomas and other benign mesenchymal tumors, implying a role for this gene in abnormal cell proliferation. In breast carcinomas, CRD-BP expression and or gene copy number gains in the region encompassing the c-myc locus were detected in approximately 75% of tumors, implying that the deregulated expression of c-myc may be more widespread than previously believed. Infiltrated lymph nodes, corresponding to CRD-BP-positive primary tumors, were also found positive indicating that monitoring for CRD-BP could prove useful for the detection and monitoring of disseminated disease.
Authors:
P Ioannidis; L Mahaira; A Papadopoulou; M R Teixeira; S Heim; J A Andersen; E Evangelou; U Dafni; N Pandis; T Trangas
Related Documents :
14751824 - Therapeutic potentialities of ews-fli-1 mrna-targeted vectorized antisense oligonucleot...
11403924 - Expression of the prothymosin alpha mrna correlated with that of n-myc in neuroblastoma.
7686084 - The nephrotoxin dichlorovinylcysteine induces expression of the protooncogenes c-fos an...
17652624 - High skp2 expression characterizes high-risk neuroblastomas independent of mycn status.
9722564 - Hrt, a novel zinc finger, transcriptional repressor from barley.
16321974 - Transient ikappab kinase activity mediates temporal nf-kappab dynamics in response to a...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Anticancer research     Volume:  23     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    2003 May-Jun
Date Detail:
Created Date:  2003-08-04     Completed Date:  2003-08-19     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  2179-83     Citation Subset:  IM    
Affiliation:
Department of Genetics, St Savvas Hospital, Athens, Greece. pioannidis@ath.forthnet.gr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antigens, Neoplasm / biosynthesis,  genetics,  physiology*
Gene Expression Regulation, Developmental
Humans
Neoplasms / genetics,  metabolism
Proto-Oncogene Proteins c-myc / biosynthesis,  genetics*
RNA, Messenger / genetics,  metabolism*
RNA-Binding Proteins / biosynthesis,  genetics,  physiology*
Chemical
Reg. No./Substance:
0/Antigens, Neoplasm; 0/IMP-1 protein, human; 0/Proto-Oncogene Proteins c-myc; 0/RNA, Messenger; 0/RNA-Binding Proteins; 0/oncofetal antigens

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ets-2 interacts with co-repressor BS69 to repress target gene expression.
Next Document:  Study of the mechanisms of cigarette smoke gas phase cytotoxicity.